Patients with narcolepsy type 1 continue to experience residual disease burden despite guideline-recommended therapy However, orexin-targeted therapies are showing promising results in trials... 📈 >> Selective hypocretin receptor agonists, designed to directly restore orexin signalling << 📺 Sleep Medicine expert, Prof. Yves Dauvilliers takes us through the evolution of narcolepsy type 1 care in this case-based animated video Programme endorsed by ANC & Reference Centre for Narcolepsy and Rare Hypersomnias Supported by an Independent Educational Grant from Takeda

America’s drug regulator has already approved an orexin agonist for narcolepsy, a disorder that leaves patients excessively sleepy by day and prone to nod off without warning. But hopes for this new drug type do not end there

China is the first country to approve a breakthrough narcolepsy drug from Japan’s Takeda Pharmaceutical, underscoring how Beijing’s regulatory overhaul is prompting global drugmakers to debut new therapies in the country ahead of the U.S. and Europe.

Today in Caixin’s Business Brief: - Beijing approves first-in-class drug targeting narcolepsy - China to build charging, battery-swapping stations for electric heavy trucks - Anthropic agrees to $1.5 billion settlement in a lawsuit brought by authors